Free tool
FAERS Monitor: Flagyl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020334 or its brand name (Flagyl, Metronidazole). Reports on generic versions are filed under their own applications.
Reports
63,834
Serious
53,748
84% of reports
Hospitalization
27,270
Death reported
6,909
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective5,512
- nausea4,677
- off label use4,209
- diarrhoea4,084
- vomiting3,308
- pyrexia3,224
- drug hypersensitivity3,164
- pain3,035
- abdominal pain3,004
- headache2,880
- fatigue2,803
- dyspnoea2,244
- dizziness2,182
- condition aggravated2,166
- malaise2,000
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 768 |
| 2005 | 819 |
| 2006 | 874 |
| 2007 | 887 |
| 2008 | 767 |
| 2009 | 1,179 |
| 2010 | 1,432 |
| 2011 | 1,903 |
| 2012 | 2,383 |
| 2013 | 2,164 |
| 2014 | 2,426 |
| 2015 | 3,273 |
| 2016 | 3,757 |
| 2017 | 3,481 |
| 2018 | 5,261 |
| 2019 | 5,610 |
| 2020 | 4,735 |
| 2021 | 4,501 |
| 2022 | 3,972 |
| 2023 | 3,936 |
| 2024 | 3,586 |
| 2025 | 3,743 |
| 2026 | 2,373 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,990,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 3,164 | 5.5 | 5.3 | 11,439 |
| abdominal painSignal | 3,004 | 4.3 | 4.1 | 7,583 |
| pyrexiaSignal | 3,224 | 3.1 | 3.0 | 4,587 |
| condition aggravatedSignal | 2,166 | 2.4 | 2.3 | 1,704 |
| vomitingSignal | 3,308 | 2.3 | 2.3 | 2,543 |
| diarrhoeaSignal | 4,084 | 2.1 | 2.0 | 2,384 |
| nausea | 4,677 | 2.0 | 1.9 | 2,245 |
| pain | 3,035 | 1.6 | 1.6 | 759 |
| off label use | 4,209 | 1.6 | 1.5 | 947 |
| headache | 2,880 | 1.5 | 1.5 | 518 |
| malaise | 2,000 | 1.5 | 1.4 | 344 |
| dizziness | 2,182 | 1.4 | 1.4 | 303 |
| drug ineffective | 5,512 | 1.4 | 1.3 | 611 |
| dyspnoea | 2,244 | 1.3 | 1.3 | 166 |
| fatigue | 2,803 | 1.2 | 1.1 | 85 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.